An enzyme-linked immunosorbent assay to study bevacizumab pharmacokinetics

Therapeutic Drug Monitoring

Volumn 32, Issue 5, 2010, Pages 647-652

  Ternant, David ^a,b,e   Cézé, Nicolas ^a,b,c   Lecomte, Thierry ^a,b,c   Degenne, Danielle ^a,b,d   Duveau, Anne Claire ^a,b   Watier, Hervé ^a,b,d   Dorval, Etienne ^a   Paintaud, Gilles ^a,b,e  

^a UNIVERSITÉ DE TOURS   (France)

^b CNRS   (France)

^c Departments of Gastroenterology   (France)

^d Departments of Immunology   (France)

^e UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

bevacizumab; enzyme linked immunosorbent assay; pharmacokinetics; therapeutic drug monitoring

Indexed keywords

BEVACIZUMAB; CETUXIMAB; VASCULOTROPIN 165;

ACCURACY; ADULT; AGED; ARTICLE; CALIBRATION; CLINICAL ARTICLE; COLORECTAL CANCER; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; METASTASIS; MICROTITER PLATE ASSAY; PRIORITY JOURNAL; REPRODUCIBILITY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; COLORECTAL NEOPLASMS; DRUG MONITORING; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS;

EID: 77957272872     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181ef582a     Document Type: Article

References (19)

1. Magdelaine-Beuzelin C, Kaas Q, Wehbi V, et al. Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment. Crit Rev Oncol Hematol. 2007;64:210-225.
2. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362:841-844.
3. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-676.
4. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 2005;65:671-680.
5. Approval package for:Application number STN-12508510.Available at: http:// www.fda.gov/cder/foi/nda/2004/STN-125085-Avastin-BioPharmr.pdf. Accessed September 7, 2007.
6. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357: 2666-2676.
7. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355: 2542-2550.
8. Ainsworth NL, Lee JS, Eisen T. Impact of anti-angiogenic treatments on metastatic renal cell carcinoma. Expert Rev Anticancer Ther. 2009;9: 1793-1805.
9. Tong RT, Boucher Y, Kozin SV, et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004;64:3731-3736.
10. Herbst RS, Johnson DH, Mininberg E, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-smallcell lung cancer. J Clin Oncol. 2005;23:2544-2555.
11. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
12. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-434.
13. Gordon CR, Rojavin Y, Patel M, et al. A review on bevacizumab and surgical wound healing: an important warning to all surgeons. Ann Plast Surg. 2009;62:707-709.
14. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001;19: 843-850.
15. Lu JF, Bruno R, Eppler S, et al. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol. 2008;62: 779-786.
16. US Food and Drug Administration.Approval package for Avastin. 2004. Application number STN-12508510. http://www.fda.gov/cder/foi/ nda/2004/STN-125085-Avastin-BioPharmr.pdf. Accessed September 7, 2007.
17. Delbaldo C, Pierga JY, Dieras V, et al. Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. Eur J Cancer. 2005;41: 1739-1745.
18. Winnonmix Professional 2.0.1 User's Guide. Mountain View, CA: Pharsight Corp; 2000
19. Margolin K, Gordon MS, Holmgren E, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol. 2001;19:851-856.